

***Request under Freedom of Information Act 2000***

Thank you for your request for information which we received on Friday 11<sup>th</sup> August 2023. I am pleased to confirm the following.

**Q1. How many patients were treated in July 2023 (or latest available month) by the Dermatology department with the following drugs:**

- Abrocitinib (Cibinqo) 0 patients
- Baricitinib (Olmiant) 3 patients
- Dupilumab (Dupixent) 28 patients
- Omalizumab (Xolair) 2 patients
- Tralokinumab (Adtralza) 0 patients
- Upadacitinib (Rinvoq) 0 patients

**Q2. How many patients were treated in July 2023 (or latest available month) by the Respiratory Medicine department with the following drugs:**

- Benralizumab (Fasenra) 0 patients
- Dupilumab (Dupixent) 0 patients
- Mepolizumab (Nucala) 0 patients
- Omalizumab (Xolair) 0 patients
- Reslizumab (Cinqaero) 0 patients
- Tezepelumab (Tezspire) 0 patients

We are not commissioned to supply these drugs for respiratory conditions.

Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.